i49

I-49 free base (Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-6-(tetrahydro-2H-pyran-4-yl)-) is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.

IPI-493 (17-amino17demethoxy) is a novel HSP90 inhibitor with antitumor activity.

BI-4916 is a selective phosphoglycerate dehydrogenase (PHGDH) inhibitor that inhibits SSP and reduces the migration of cancer cells.BI-4916 can be used in the study of cancer and metabolic diseases.

BI-4924 is a selective and potent inhibitor of phosphoglycerate dehydrogenase (PHGDH) (IC50=3 nM) that disrupts serine biosynthesis by intracellular trapping, and can be used in the study of diseases caused by dysfunction.

JH-VIII-49 is an effective and selective inhibitor of CDK8.

ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase, with an EC50 value of 40 nM in cell.

NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor with significant affinity for various BRD4 and BRDT isoforms, as demonstrated by its Kd values of 0.095 nM for BRD4-1, 0.32 nM for BRD4-2, 0.29 nM for BRD4-T, 0.089 nM for BRDT-1, 5.5 nM for BRDT-2, and 0.058 nM for BRDT-T. Additionally, NC-III-49-1 exhibits antiproliferative effects and reduces the expression of c-Myc [1].

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Dazodalibep (MEDI 4920; VIB 4920) is a monoclonal antibody that specifically targets CD40LG/TNFSF5 and is fused to human serum albumin (ALB/HSA) [1].

E10i-494 is an ionizable cationic branched endosomal disruptor (BEND) lipid utilized in the formation of lipid nanoparticles (LNPs) for mRNA delivery in vitro. These LNPs, encapsulating mCherry or luciferase mRNA, trigger the expression of mCherry or luciferase in T cells.